Navigation Links
TopoTarget Successfully Buys Back Full Control of Belinostat
Date:4/22/2008

Consolidates the Global Rights for the Product TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating

the Global Rights for the Product

TopoTarget Acquires US & RoW Rights From CuraGen Corporation

COPENHAGEN, April 22 /PRNewswire/ --

- Deal Covers a Payment of USD 26 million (DKK 122.8 million), a Total of 5 Million TopoTarget Shares and a Commercial Milestone Payment

- Webcast Conference Call to be Held 2pm CET

TopoTarget A/S (OMX: TOPO) today announced that the company has successfully gained full control of belinostat so that global rights are now wholly owned by the company. Belinostat is TopoTarget's lead product in clinical development and is due to enter registration trial in the second half of this year.

Belinostat is a potential blockbuster product, has shown positive results when tested in patients including proof of concept in Cutaneous and Peripheral T-Cell Lymphoma (CTCL and PTCL) and very promising effect in treating ovarian cancer in combination with standard chemotherapy drugs. The product has been developed for multiple cancer indications jointly by TopoTarget and CuraGen Corporation since 2004. TopoTarget, which has already one product approved in the EU and US, plans to develop belinostat to the market in initial indications and will seek a large pharma partner in order to fully optimise the product's blockbuster potential.

"CuraGen has been a good partner and helped us over a high risk period," said Dr. Peter Buhl Jensen, CEO of TopoTarget. "More than 500 patients have been treated with belinostat, and we are very enthusiastic about its efficacy and safety. I believe that this drug is broadly applicable and unique in its flexible dosing, and its lack of toxicity."

CuraGen has accepted to sell their rights back to TopoTarget and under the agreement will receive USD 26 million (approximately DKK 122.8 million), 5 million new Topo
'/>"/>

SOURCE TopoTarget A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
2. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
3. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
4. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Life on Mars pregnancy test successfully launched
7. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. Citrate appears to control buckyball clumping but environmental concerns remain
10. Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
11. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... HILLS, Mass., Dec. 5 MacroChem,s,(OTC Bulletin Board: MACM), ... at the upcoming Equities Magazine Winter Discovery,Day Conference XV ... December 7,2007. Mr. DeLuccia is scheduled to present at ... an all day event featuring special,presentations from emerging public ...
... Md., Dec. 5 Micromet, Inc. (Nasdaq:,MITI), a ... antibody-based products for cancer, inflammation and autoimmune,diseases, today ... Officer of Micromet, will be part of a ... Therapies For Cancer" at the 2007,RBC Capital Markets ...
... Dec. 5 Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ... study with an undisclosed global leader in the production ... Factor IX protein,which is currently administered by injection to ... "We look forward to working with our new global ...
Cached Biology Technology:MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 2MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 3Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007 2Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
... Mouse monoclonal [E12] to MAP1 Light Chain ... the physical interactions between microtubules and components of ... a heavy chain subunit and multiple light chain ... one of the light chain subunits and can ...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: